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Abstract
Background: Catalytic RNA molecules are called ribozymes. The aptamers are DNA or RNA
molecules that have been selected from vast populations of random sequences, through a
combinatorial approach known as SELEX. The selected oligo-nucleotide sequences (~200 bp in
length) have the ability to recognize a broad range of specific ligands by forming binding pockets.
These novel aptamer sequences can bind to nucleic acids, proteins or small organic and inorganic
chemical compounds and have many potential uses in medicine and technology.
Results: The comprehensive sequence information on aptamers and ribozymes that have been
generated by in vitro selection methods are included in this RiboaptDB database. Such types of
unnatural data generated by in vitro methods are not available in the public 'natural' sequence
databases such as GenBank and EMBL. The amount of sequence data generated by in vitro selection
experiments has been accumulating exponentially. There are 370 artificial ribozyme sequences and
3842 aptamer sequences in the total 4212 sequences from 423 citations in this RiboaptDB. We
included general search feature, and individual feature wise search, user submission form for new
data through online and also local BLAST search.
Conclusion: This database, besides serving as a storehouse of sequences that may have diagnostic
or therapeutic utility in medicine, provides valuable information for computational and theoretical
biologists. The RiboaptDB is extremely useful for garnering information about in vitro selection
experiments as a whole and for better understanding the distribution of functional nucleic acids in
sequence space. The database is updated regularly and is publicly available at http://mfgn.usm.edu/
ebl/riboapt/.
Background
Until about 25 years ago, all known enzymes were pro-
teins. But then it was discovered that some RNA molecules
also have enzymatic property; that is, catalyze covalent
changes in the structure of substrates (most of which are
also RNA molecules) [1-3]. Catalytic RNA molecules are
called ribozymes. Since the discovery of ribozymes that
exist in living organisms, there has been a lot of interest in
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the study of new synthetic ribozymes made in the labora-
tory. First Tang and Breaker [4] lab isolated self-cleaving
RNAs originating from random-sequence RNAs by using
in vitro selection method. A large number of self-cleaving
RNAs have been produced that have good enzymatic
activity [5-7]. Some of the synthetic ribozymes that were
produced had novel structures, while some were similar to
the naturally occurring hammerhead ribozyme [2,8].
The aptamers are DNA or RNA molecules, possessing
desirable affinity, selected by SELEX – Systemic Evolution
of Ligands by Exponential enrichment method. This
SELEX method is an in vitro iterative process that isolates
binding aptamers from the random pool and amplifies
each sequence by the polymerase chain reaction after each
round of isolation [9-16]. The selected oligo-nucleotide
sequences (~200 bp in length) have the ability to recog-
nize specific ligands by forming binding pockets and can
bind to nucleic acids, proteins or small organic, inorganic
chemical compounds and even small organisms like
viruses [17-25].
Aptamers are a promising class of compounds, both for
target validation and therapy. As designer drugs, they
exhibit high specificity, high affinity, and modifiable bio-
availability [26-30]. The ability to generate inhibitors with
such properties against a variety of target proteins will be
invaluable as the human genome and proteome are deci-
phered [12,31-37].
The RiboaptDB is not only extremely useful both for iden-
tifying available aptamers and artificial ribozymes. It is
also useful for acquiring information about in vitro selec-
tion experiments like the type of the nucleic acid, type of
the target and conditions of the experiment as a whole
and for better understanding the distribution of func-
tional nucleic acids in the given sequence space. Like other
types of sequences, the amount of sequences generated by
in vitro selection experiments has been accumulating
exponentially [10,14]. The sheer number and diversity of
selection experiments has risen to the point where it is
now essential to gather all the sequence data into a com-
prehensive, continuously updated database. The general
sequence databases like GenBank, EMBL and DDBJ do
not maintain the complete collection of artificial nucleic
acid sequences like aptamer and ribozyme. Another data-
base, 'Aptamer database' also contains lot of information
on this type of data but not regularly updating with new
data [38,39].
Construction and Content
Structure and implementation
The design of the RiboaptDB database schema follows the
three level schema architecture as shown in the Figure 1.
The database has been implemented using open source
relational database MySQL [40] server version 4.1. The
user-friendly web interface has been developed by using
PHP language [41]. The web server is an open source
Apache web server version 2.0. The figure 2 shows the
Entity-Relationship (ER) schema of the database.
The "sequence" table is the key table in the database to
which all other tables are related directly or indirectly.
This table contains the sequence ID and relates directly
with its child tables, "aptamer" and "ribozyme", which
contains the corresponding sequence information. The
other important tables in the database are "publication"
and "experiment" which store the citation information
like title, journal name, authors, pubmed ID and experi-
ment details like template type and experiment condi-
tions respectively. The target specific information, the
target name and its category ('organic', 'inorganic',
'nucleic', 'peptide', 'protein' and 'other') obtained from
the "target" table. If any information about non-canonical
base pair is available, it can be retrieved through the "non-
canonical" table.
Content
RiboaptDB is relatively small database but is, nonetheless,
essentially complete. The data was sourced from a previ-
ous compilation and exhaustive searching of the primary
literature. The current size of the database 4212 sequences
from 423 citations.
In this, there are 370 artificial ribozyme sequences and
3842 aptamer sequences in the total 4212 sequences. The
database is updated every month as new literature comes
Schematic illustration of three tier architecture of the  RiboaptDB Figure 1
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on aptamers and artificial ribozyme seqences. The intial
collection of data is done through searching the NCBI-
Pubmed for the literature with keywords like 'artificial
ribozymes', 'ribozyme', 'aptamers', 'SELEX' etc. The useful-
ness of a database is governed by the accuracy of the data
it contains. The data in this database is compiled manu-
ally from previous published, peer-reviewed articles, and
verified.
Utility and Discussion
RiboaptDB provides users with an easy-to-use web inter-
face with flexibility to select either ribozyme or aptamer
sequences to browse the corresponding information.
Beginning at the welcome page (Figure 3), the user can
navigate via the top menu or the browse database tables
on the side menu. A brief description about the navigation
is given below.
Search
The general complete search option provides an interface
for a variety number of queries to the database. It can be
used to search the database for sequence, experiment, tar-
get, author, publication and non-canonical along with
either ribozyme or aptamer or both and also either natural
or artificial type of sequences.
Local Blast
The local Blast option can be used to do blast search
against the local archived data to perform sequence-simi-
larity searches using the BLAST family of programs (Figure
4). This will useful to user to know the most similar
sequences to the submitted sequences and also useful to
know further information about its target and experiment
details (Figure 5).
Submit data
It facilitates online sequence submission to the database.
It allows users to fill in a form containing new sequence
The schema and the dataflow of the RiboaptDB Figure 2
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information along with user details (Figure 6). Related
information can also be submitted through uploading a
text file. The data which is then saved into a directory on
the server side and an email is sent automatically to the
curator who then checks the data to make sure there are
no errors and then the information is loaded into the
database automatically.
Alternate to the general search option on top menu, there
is a search option on the side menu on the home page to
search the whole database on a specific keyword. Also,
specific table search is available on side menu of each
related pages. The user can also retrieve the selected
sequences into a text file for further studies.
The idea behind the combining of ribozymes and aptam-
ers data into one database is, increasing the chance of gen-
erating ribozymes with modified and novel properties
[26]. One example is combining both the 'target identifi-
cation' of aptamer and 'catalytic activity' of ribozymes
into a commercial 'riboswitch' application [42-45].
Future Perspectives
RiboaptDB project is young. With respect to future work,
the database needs to be maintained and developed regu-
larly, ensuring our links to external databases remain up
to date and newly published data is added. Initially, as
with all databases, random errors will have occurred due
to human error during the data accumulation or will be
extant within the original experimental data. The database
will be assessed for errors and inconsistencies, thus main-
taining, as far as possible, the overall veracity of our data.
View of experiment details Figure 5
View of experiment details.
Screenshot of the homepage of the RiboaptDB, an user  friendly interface for the database Figure 3
Screenshot of the homepage of the RiboaptDB, an user 
friendly interface for the database.
Screenshot of the local BLAST page with default options Figure 4
Screenshot of the local BLAST page with default options.BMC Bioinformatics 2006, 7(Suppl 2):S6
Page 5 of 6
(page number not for citation purposes)
Conclusion
The goal of RiboaptDB constructors was the collection of
all ribozyme and aptamer sequences that have appeared
to date and their detailed and correct annotation. The ease
of access to the data is of great importance and the
bespoke search system and the inclusion of a BLAST
search greatly facilitates this. The better the organisation
of the data, the easier the work will be for researchers deal-
ing with aptamers and ribozymes.
Availability and Requirements
RiboaptDB was created and is maintained in the Depart-
ment of Biological Sciences at the University of Southern
Mississippi. It is publicly available at the http://
mfgn.usm.edu/ebl/riboapt/.
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